OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the anticipated release of comprehensive efficacy data from its Phase 2 trial of OK-101 in dry eye disease (DED) on March 22.
The event, scheduled to start at 12pm ET is poised to offer a detailed exploration of the trial's findings, featuring presentations from renowned specialists, including Jay Pepose and Anat Galor.
Dr Pepose, with nearly four decades of experience as a clinician and researcher, brings extensive expertise to the discussion, while Dr Galor's focus on understanding the mechanisms of pain in dry eye adds valuable insights.
OK-101, a lipid-conjugated chemerin peptide agonist targeting inflammatory responses, has shown promising results in previous data readouts. Notably, it demonstrated significant improvements in both FDA-recognized efficacy endpoints and symptoms of DED, such as burning, stinging and blurred vision.
This data is particularly significant given the lack of FDA-approved therapies for neuropathic corneal pain, a condition often associated with DED.
OKYO Pharma is a clinical-stage biopharmaceutical company specializing in innovative therapies for inflammatory DED and neuropathic corneal pain (NCP), with ongoing Phase 2 trials for OK-101 targeting both conditions.